Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 6/30
$2.71+0.04 (+1.50%)
Close on Nov 18, 2026Market cap $94.21MP/E –Yield –
Anixa Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Anixa Biosciences's operating cash flow for the twelve months ending Jul 31, 2026 was -$7.38M. For fiscal 2025 it was -$7.17M. The highest annual figure on record is $1.36M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$7.17M | – |
| FY2024 | Oct 31, 2024 | -$7.34M | – |
| FY2023 | Oct 31, 2023 | -$6.21M | – |
| FY2022 | Oct 31, 2022 | -$6.49M | – |
| FY2021 | Oct 31, 2021 | -$4.94M | – |
| FY2020 | Oct 31, 2020 | -$6.18M | – |
| FY2019 | Oct 31, 2019 | -$4.74M | – |
| FY2018 | Oct 31, 2018 | -$4.27M | – |
| FY2017 | Oct 31, 2017 | -$3.80M | – |
| FY2016 | Oct 31, 2016 | -$3.38M | -348.0% |
| FY2015 | Oct 31, 2015 | $1.36M | – |
| FY2014 | Oct 31, 2014 | -$2.38M | – |
| FY2013 | Oct 31, 2013 | -$3.19M | – |
| FY2012 | Oct 31, 2012 | -$3.14M | – |
| FY2011 | Oct 31, 2011 | -$716.00K | – |
| FY2010 | Oct 31, 2010 | -$2.41M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$1.77M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$1.74M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$2.61M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$1.26M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$1.51M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$1.50M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$2.90M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$927.00K | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$2.64M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$1.46M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$2.31M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$1.97M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$1.45M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$807.00K | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$1.99M | – |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | -$1.59M | – |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | -$1.40M | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$2.31M | – |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -$1.20M | – |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$1.05M | – |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | -$1.48M | – |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | -$1.24M | – |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | -$1.17M | – |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -$1.41M | – |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -$1.29M | – |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -$1.56M | – |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -$1.91M | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -$1.34M | – |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -$640.10K | – |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | -$1.43M | – |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | -$1.33M | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -$1.02M | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -$1.17M | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$742.49K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$1.34M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$739.29K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$1.25M | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$1.08M | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$729.91K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$682.99K | – |
See a number that looks wrong?